JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.63B |
| 2 |
JPMorgan BetaBuilders Japan ETF
BBJP
|
+$1.83B |
| 3 |
JPMorgan BetaBuilders International Equity ETF
BBIN
|
+$1.55B |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$1B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$884M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI EAFE ETF
IEFA
|
+$1.8B |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$1.77B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$884M |
| 4 |
iShares Core US Aggregate Bond ETF
AGG
|
+$880M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$834M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.09% |
| 2 | Technology | 16.19% |
| 3 | Financials | 10.76% |
| 4 | Healthcare | 10.54% |
| 5 | Consumer Discretionary | 10.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
DNR
4126
DELISTED
Denbury Resources, Inc.
DNR
| $186K | ﹤0.01% |
672,022
-3,462,779
| -84% | -$1.04M |
2013 Q2
28 quarters
|
|
|
EIDX
4127
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $185K | ﹤0.01% |
3,875
-12,517
| -76% | -$582K |
2018 Q3
7 quarters
|
|
|
AGEN
4128
Agenus
AGEN
$394M
| $184K | ﹤0.01% |
2,380
+586
| +33% | +$35.1K |
2017 Q3
11 quarters
|
|
4129
Carlyle Secured Lending
CGBD
$727M
| $184K | ﹤0.01% |
21,507
-13,147
| -38% | -$103K |
2018 Q2
8 quarters
|
|
|
SCHV
4130
Schwab US Large-Cap Value ETF
SCHV
$15.3B
| $184K | ﹤0.01% |
10,998
-192
| -2% | -$3.13K |
2017 Q3
11 quarters
|
|
|
EIGI
4131
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $184K | ﹤0.01% |
45,623
-100,150
| -69% | -$296K |
2016 Q4
14 quarters
|
|
|
NVEE
4132
DELISTED
NV5 Global
NVEE
| $183K | ﹤0.01% |
14,336
+696
| +5% | +$7.83K |
2017 Q3
11 quarters
|
|
|
AERI
4133
DELISTED
Aerie Pharmaceuticals
AERI
| $183K | ﹤0.01% |
12,428
-1,492
| -11% | -$22.1K |
2017 Q4
10 quarters
|
|
4134
Artesian Resources
ARTNA
$345M
| $182K | ﹤0.01% |
5,013
-19,056
| -79% | -$670K |
2013 Q2
28 quarters
|
|
4135
State Street SPDR S&P 400 Mid Cap Value ETF
MDYV
$2.72B
| $182K | ﹤0.01% |
4,265
+2,020
| +90% | +$81.4K |
2019 Q4
2 quarters
|
|
4136
Red River Bancshares
RRBI
$678M
| $182K | ﹤0.01% |
4,148
-3,914
| -49% | -$153K |
2019 Q2
4 quarters
|
|
4137
PUT
Eli Lilly
LLY
$1.02T
| $181K | ﹤0.01% |
1,100
-99,600
| -99% | -$15.3M |
2016 Q3
15 quarters
|
|
4138
PUT
Thermo Fisher Scientific
TMO
$250B
| $181K | ﹤0.01% |
500
| – | – |
2018 Q2
8 quarters
|
|
|
ZEUS
4139
DELISTED
Olympic Steel
ZEUS
| $181K | ﹤0.01% |
15,443
+8,265
| +115% | +$81.8K |
2016 Q1
17 quarters
|
|
4140
Grid Dynamics Holdings
GDYN
$636M
| $179K | ﹤0.01% |
+25,967
| New | +$213K |
2020 Q2
0 quarters
|
|
4141
Ovid Therapeutics
OVID
$457M
| $179K | ﹤0.01% |
24,316
-60,537
| -71% | -$283K |
2017 Q4
10 quarters
|
|
4142
CALL
PNC Financial Services
PNC
$87.9B
| $179K | ﹤0.01% |
+1,700
| New | +$179K |
2020 Q2
0 quarters
|
|
4143
Southern First Bancshares
SFST
$575M
| $179K | ﹤0.01% |
6,440
-4,936
| -43% | -$134K |
2017 Q4
10 quarters
|
|
4144
OrthoPediatrics
KIDS
$598M
| $178K | ﹤0.01% |
4,076
-32,651
| -89% | -$1.47M |
2017 Q4
10 quarters
|
|
|
IGMS
4145
DELISTED
IGM Biosciences
IGMS
| $175K | ﹤0.01% |
2,394
+806
| +51% | +$49K |
2019 Q4
2 quarters
|
|
4146
Lennar Class B
LEN.B
$17.7B
| $175K | ﹤0.01% |
4,003
+3,874
| +3,003% | +$146K |
2013 Q2
28 quarters
|
|
4147
Sprout Social
SPT
$617M
| $175K | ﹤0.01% |
6,499
-7,292
| -53% | -$160K |
2020 Q1
1 quarter
|
|
4148
Fidelity D&D Bancorp
FDBC
$320M
| $174K | ﹤0.01% |
3,612
-1,211
| -25% | -$48.5K |
2018 Q2
8 quarters
|
|
|
SMMF
4149
DELISTED
Summit Financial Group, Inc.
SMMF
| $174K | ﹤0.01% |
10,556
-7,893
| -43% | -$130K |
2017 Q4
10 quarters
|
|
|
SBE.WS
4150
DELISTED
Switchback Energy Acquisition Corporation Warrants, exercisable for one share of Class A Common Stoc
SBE.WS
| – | – |
0
| – | – |
2020 Q1
1 quarter
|
|
Similar funds
JP Morgan Chase's Q2 2020 Portfolio in Review
As of Q2 2020, JP Morgan Chase held 5,976 positions worth $518B, up 22% from $426B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q2 2020 filing shows 640 new, 2,055 increased, 2,340 reduced and 398 closed positions. Its largest new stake was JPMorgan BetaBuilders International Equity ETF: 35,626,738 shares worth $1.64B. The largest sale was iShares Core MSCI EAFE ETF, an estimated $1.8B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 28% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2020 buy was JPMorgan BetaBuilders International Equity ETF: 35,626,738 shares worth $1.64B.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q2 2020, an estimated $2.63B increase.
- JP Morgan Chase's biggest Q2 2020 reduction was iShares Core MSCI EAFE ETF, cutting an estimated $1.8B.
- JP Morgan Chase fully exited Allergan plc in Q2 2020, selling an estimated $656M.
- JP Morgan Chase's ten largest holdings make up 17% of its $518B portfolio in Q2 2020.
- JP Morgan Chase opened 640 new positions and closed 398 in Q2 2020.
- JP Morgan Chase's portfolio value rose 22% quarter-over-quarter to $518B.
Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.